BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/16/2025 5:36:37 AM | Browse: 89 | Download: 551
 |
Received |
|
2024-11-01 08:53 |
|
Peer-Review Started |
|
2024-11-20 02:01 |
|
First Decision by Editorial Office Director |
|
2024-12-17 05:39 |
|
Return for Revision |
|
2024-12-17 05:39 |
|
Revised |
|
2024-12-31 03:28 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-01-21 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-01-21 09:25 |
|
Articles in Press |
|
2025-01-21 09:25 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-02-27 01:54 |
|
Publish the Manuscript Online |
|
2025-04-16 05:36 |
| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
Diarylpentanoid, a curcumin analog, inhibits malignant meningioma growth in both in vitro and in vivo models
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Anna Terasawa, Kazuhiro Shimazu, Hiroshi Nanjo, Masatomo Miura and Hiroyuki Shibata |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| TAIHO Pharmaceutical |
AS2023A000122715 |
| Nippon Kayaku |
NKCS20230416001 |
|
| Corresponding Author |
Hiroyuki Shibata, MD, PhD, Professor, Department of Clinical Oncology, Akita University Graduate School of Medicine, Hondo 1-1-1, Akita 010-8543, Japan. hiroyuki@med.akita-u.ac.jp |
| Key Words |
Malignant meningioma; Curcumin; Diarylpentanoid curcumin analog; Hepatocellular growth factor; Nuclear factor kappa B; N-cadherin |
| Core Tip |
Malignant meningiomas have a poor prognosis, but drug development is limited due to their rarity. The curcumin analog GO-Y030 showed approximately 10-16 times stronger inhibitory effects than curcumin on IOMM-Lee and HKBMM cell lines, in vitro. Intraperitoneal administration of GO-Y030 also significantly inhibited the growth of malignant meningiomas, IOMM-Lee inoculated in nude mouse models. GO-Y030 significantly inhibited hepatocyte growth factor, nuclear factor kappa B, and N-cadherin, which contribute to epithelial-mesenchymal transition. |
| Publish Date |
2025-04-16 05:36 |
| Citation |
Terasawa A, Shimazu K, Nanjo H, Miura M, Shibata H. Diarylpentanoid, a curcumin analog, inhibits malignant meningioma growth in both in vitro and in vivo models. World J Exp Med 2025; 15(2): 102897 |
| URL |
https://www.wjgnet.com/2220-315x/full/v15/i2/102897.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v15.i2.102897 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
